Quadruple plasma blood purification device and purification method

Abstract

The invention provides a quadruple plasma blood purification device and purification method. The quadruple plasma blood purification device comprises a primary plasma separator, a secondary plasma separator, a perfusion device and a dialyzer, the inlet of the primary plasma separator is connected with the artery of a patient; an inlet of the secondary plasma separator is connected with the primary plasma separator; an inlet of the perfusion device is connected with the secondary plasma separator; and the dialyzer is respectively connected with the perfusion device and the primary plasma separator. According to the technology, only one-time operation is needed for treatment for 6-12 hours, multiple operations are not needed, meanwhile, the core pathogenesis of hypertriglyceridemia, cytokine storm sepsis, internal environment disorder and renal insufficiency which cause pancreatitis is solved, the treatment time is saved to a great extent, the risk that the illness state develops to death is reduced, and the treatment cost is reduced. The clinical effective treatment rate is improved; in addition, only one set of equipment is needed, and the device has the advantages of low cost, simplicity and convenience in operation, low time, manpower and financial resource consumption, high treatment efficiency and the like.

Description

Technical Field

[0001] The present invention relates to the technical field of blood purification, in particular to a quadruple plasma blood purification device and a purification method. Background Art

[0002] Hypertriglyceridemic severe acute pancreatitis (HTG-SAP) is a common critical disease of the digestive system, with a mortality rate of about 40%. The pathogenesis of hyperlipidemic severe acute pancreatitis (HL-SAP) mainly includes three aspects: hypertriglyceridemia, cytokine storm sepsis (CSS), and internal environment imbalance. It can induce multiple organ failure and lead to death. At present, the main clinical treatment methods are multidisciplinary comprehensive treatment and selective blood purification support. Most reports abroad focus on plasma exchange treatment, while domestic treatment mainly focuses on hemodialysis (HDF), hemoperfusion (PA), plasma exchange, and double plasma exchange (DFPP). However, plasma exchange, hemodialysis, perfusion, and continuous plasma filtration adsorption cannot simultaneously and efficiently solve problems such as hypertriglyceridemia, cytokine storm sepsis, internal environment imbalance, and renal insufficiency, which increases the risk of progression of HTG-SAP patients in the critical stage. In view of the current thinking of domestic and foreign scholars on the clinical treatment experience of hyperlipidemia severe acute pancreatitis, I have long studied non-bioartificial liver technology and blood purification technology, creatively combined the three core technologies of DFPP, ​​HDF and PA, and proposed the Quadruple Plasma Purification System (QPPS) for the first time in China and applied it clinically, solving the four core problems of HTG-SAP high triglycerides, cytokine storm sepsis, internal environment imbalance, and renal function damage at one time. At present, the clinical efficacy of 5 patients has been observed to be significant. This technology is unique in China, and the research on this new technology in China has not been reported yet. It is in the advanced technical field and scientific research frontier at home and abroad. This technology does not involve the sharing and theft of other technologies and patents. The clinical research of QPPS in the treatment of HL-SAP has great social value and scientific prospects.

[0003] For severe hyperlipidemia-induced acute pancreatitis, current domestic and international guidelines and expert consensus all use hemodialysis or continuous hemofiltration or plasma exchange or plasma perfusion. The technical disadvantages include: the existing technical treatment time requires more than 24-48 hours at a time, divided into three different treatment modes, which sequentially treat the causes of hypertriglyceridemia, cytokine storm, internal environment disorders, renal insufficiency, etc., which invisibly increases the risk of further deterioration or even death for patients who are already in critical condition; in addition, the existing technical treatment process requires a total of 4 sets of blood purification pathways, 3 primary plasma separators, one secondary plasma separator, one perfusion device, and 2-3 dialyzers, which is costly, slow in treatment response, and complicated to operate, consuming a lot of manpower, material resources, and financial resources. Summary of the invention

[0004] The object of the present invention is to provide a quadruple plasma blood purification device and purification method to solve the problems raised in the above background technology.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] A quadruple plasma blood purification device, comprising: a primary plasma separator, a secondary plasma separator, a perfusion device, and a dialyzer;

[0007] The inlet of the primary plasma separator is connected to the patient's artery, and is used to receive the patient's plasma and separate whole plasma;

[0008] The inlet of the secondary plasma separator is connected to the primary plasma separator and is used to remove macromolecules in whole plasma through the membrane;

[0009] The inlet of the perfusion device is connected to the secondary plasma separator, and is used to adsorb and remove middle-molecular toxins from the plasma after the macromolecules are removed;

[0010] The dialyzer is connected to the perfusion device and the primary plasma separator respectively, and is used to receive the plasma with middle molecule toxins removed output by the perfusion device and the blood cells output by the primary plasma separator. Dialysis fluid is pumped into the upper end of the dialyzer and mixed with the plasma with middle molecule toxins removed and the blood cells for dialysis; the filtrate is discarded at the lower end of the dialyzer, and the venous outlet of the dialyzer transports the blood back to the patient's vein.

[0011] Optionally, an arterial pump and an arterial pump are sequentially arranged on a pipeline connecting the inlet of the primary plasma separator and the patient's artery, and are used to deliver the patient's blood from the artery into the primary plasma separator.

[0012] Optionally, a separation pump is provided on the connection pipeline between the primary plasma separator and the secondary plasma separator, which is used to pump the plasma removing macromolecules to the bottom inlet of the secondary plasma separator; the top outlet of the secondary plasma separator is connected to a waste liquid bag through a waste liquid pump.

[0013] Optionally, the hemoperfusion cartridge sends the plasma removing medium molecules toxins to the bottom inlet of the dialyzer, and the primary plasma separator sends blood cells to the bottom inlet of the dialyzer; the dialyzer is connected to a filtrate bag through a filtrate pump;

[0014] The top venous end outlet of the dialyzer transports the blood back to the patient's vein through a venous chamber.

[0015] Optionally, a replacement pump is further included, which is used to input replacement fluid into the venous chamber and mix it with the blood output by the dialyzer and then input it into the patient's vein.

[0016] Optionally, the dialysate is pumped into the dialyzer through a dialysis pump.

[0017] Optionally, an OP-08 membrane is provided in the primary plasma separator; the pore size of the OP-08 membrane is 0.3 μm; an EC-50 membrane is provided in the secondary plasma separator; the pore size of the EC-50 membrane is 0.035 μm.

[0018] The present application provides a purification method for a quadruple plasma blood purification device, including:

[0019] The primary plasma separator separates the patient's blood using the OP-08 membrane and separates out the whole plasma;

[0020] The secondary plasma separator removes macromolecules in the whole plasma using the EC-50 membrane;

[0021] The hemoperfusion cartridge adsorbs and removes the medium molecules toxins in the whole plasma removing macromolecules, and transports the treated blood to the dialyzer;

[0022] The dialyzer is used to perform dialysis treatment on the dialysate, the blood cells output by the primary plasma separator, and the treated blood in a manner of diffusion and convection, and input the dialyzed blood into the patient's vein.

[0023] Optionally, before the step that the primary plasma separator separates the patient's blood using the OP-08 membrane and separates out the whole plasma, it further includes:

[0024] Inject 5 mg of dexamethasone + 5%, 20 ml of calcium gluconate, and an anticoagulant into the patient's vein; wherein, the anticoagulant is low molecular weight heparin sodium injection.

[0025] Optionally, the step dialyzer is used to perform dialysis treatment on the dialysate, blood cells output from the primary plasma separator, and processed blood in a manner of diffusion and convection.

[0026] When in input-output balance: filtrate volume (ml / h) + waste liquid volume (ml / h) = dialysate + replacement fluid volume (ml / h);

[0027] When dehydrating or ultrafiltrating: filtrate volume (ml / h) + waste liquid volume (ml / h) < dialysate + replacement fluid volume (ml / h).

[0028] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0029] A quadruple plasma blood purification device includes: a primary plasma separator, a secondary plasma separator, a hemoperfusion cartridge, and a dialyzer; the inlet of the primary plasma separator is connected to the artery of a patient and is used to receive the plasma of the patient and separate out whole plasma; the inlet of the secondary plasma separator is connected to the primary plasma separator and is used to remove macromolecules in the whole plasma within the membrane; the inlet of the hemoperfusion cartridge is connected to the secondary plasma separator and is used to adsorb and remove medium molecular toxins from the plasma after removing macromolecules; the dialyzer is respectively connected to the hemoperfusion cartridge and the primary plasma separator, and is used to receive the plasma after removing medium molecular toxins output from the hemoperfusion cartridge and receive the blood cells output from the primary plasma separator. Dialysate is pumped into the upper end of the dialyzer and mixed with the plasma after removing medium molecular toxins and blood cells for dialysis; the filtrate is discarded at the lower end of the dialyzer, and the venous end outlet of the dialyzer transports the blood back to the vein of the patient. The technology of the present invention only requires a one-time surgical treatment for 6 - 12 hours and does not require multiple surgeries. At the same time, it solves the core pathogenesis of hypertriglyceridemia, cytokine storm sepsis, internal environment disorder, and renal insufficiency that cause pancreatitis, greatly saving the treatment time, reducing the risk of the condition developing towards death, and improving the clinical effective treatment rate; in addition, only one set of blood purification pathway, one primary plasma separator, one secondary plasma separator, one dialyzer, and one hemoperfusion cartridge are required, which has the advantages of low cost, simple operation, low consumption of time, manpower, and financial resources, and high treatment efficiency. Description of the Drawings

[0030] Figure 1 It is a connection schematic diagram of an embodiment of the quadruple plasma blood purification device.

[0031] In the figure: 1. Primary plasma separator; 2. Secondary plasma separator; 3. Hemoperfusion cartridge; 4. Dialyzer; 5. Artery pump; 6. Separation pump; 7. Waste liquid pump; 8. Waste liquid bag; 9. Dialysis pump; 10. Filtrate pump; 11. Filtrate bag; 12. Replacement pump; 13. Venous pot; 14. Arterial pot. Detailed Embodiments

[0032] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0033] In addition, an element in the present invention is referred to as being "fixed to" or "disposed on" another element, which can be directly on the other element or there may also be an intermediate element. When an element is considered to be "connected to" another element, it can be directly connected to the other element or there may be an intermediate element at the same time. The terms "vertical", "horizontal", "left", "right" and similar expressions used herein are only for the purpose of illustration and do not represent the only implementation manner.

[0034] Please refer to Figure 1 , in the embodiment of the present invention, a quadruple plasma blood purification device includes: a primary plasma separator 1, a secondary plasma separator 2, a hemoperfusion cartridge 3, and a dialyzer 4; the inlet of the primary plasma separator 1 is connected to the artery of the patient and is used to receive the plasma of the patient and separate out whole plasma; the inlet of the secondary plasma separator 2 is connected to the primary plasma separator 1 and is used to remove macromolecules in the whole plasma within the membrane; the inlet of the hemoperfusion cartridge 3 is connected to the secondary plasma separator 2 and is used to adsorb and remove medium molecular toxins from the plasma after removing macromolecules; the dialyzer 4 is respectively connected to the hemoperfusion cartridge 3 and the primary plasma separator 1, and is used to receive the plasma after removing medium molecular toxins output by the hemoperfusion cartridge 3 and receive the blood cells output by the primary plasma separator 1. Dialysate is pumped into the upper end of the dialyzer 4 and mixed with the plasma after removing medium molecular toxins and blood cells for dialysis; the filtrate is discarded at the lower end of the dialyzer 4, and the venous end outlet of the dialyzer 4 conveys the blood back to the vein of the patient.

[0035] In a specific embodiment, an arterial pump 5 and an arterial pump 5 are sequentially arranged on the pipeline connecting the inlet of the primary plasma separator 1 to the artery of the patient for pumping the patient's blood from the artery into the primary plasma separator 1. A separation pump 6 is arranged on the pipeline connecting the primary plasma separator 1 and the secondary plasma separator 2 for pumping the plasma with macromolecules removed to the bottom inlet of the secondary plasma separator 2. The top outlet of the secondary plasma separator 2 is connected to a waste liquid bag 8 through a waste liquid pump 7. The hemoperfusion cartridge 3 sends the plasma with middle molecular toxins removed to the bottom inlet of the dialyzer 4, and the primary plasma separator 1 sends blood cells to the bottom inlet of the dialyzer 4. The dialyzer 4 is connected to a filtrate bag 11 through a filtrate pump 10. The top venous end outlet of the dialyzer 4 transports the blood back to the vein of the patient through a venous chamber 13. A replacement pump 12 is further included, and the replacement pump 12 is used for inputting replacement fluid into the venous chamber 13 and mixing it with the blood output by the dialyzer 4 and then inputting it into the vein of the patient. The dialysate is pumped into the dialyzer 4 through a dialysis pump 9. An OP-08 membrane is arranged in the primary plasma separator 1; the pore size of the OP-08 membrane is 0.3 μm; an EC-50 membrane is arranged in the secondary plasma separator 2; the pore size of the EC-50 membrane is 0.035 μm.

[0036] In this embodiment, referring to Figure 1As shown, the whole plasma is separated through the primary plasma separator 1OP-08 with a membrane pore size of 0.3 μm, which is the first plasma purification; the secondary plasma separator 2EC-50 with a membrane pore size of 0.035 μm is connected in series to remove macromolecules such as triglycerides inside the membrane, which is the second plasma purification; the plasma purified for the second time outside the EC-50 membrane passes through the plasma perfusion device 3 to adsorb and remove medium molecular toxins such as cytokines, which is the third plasma purification; the purified plasma is mixed with the blood cells and plasma components inside the primary plasma separator 1OP-08. The mixed blood passes through the arterial end inlet of the dialyzer 4AV600S. Dialysate is pumped into the outside of the dialyzer 4 at the upper end, and the filtrate is discarded at the lower end. The blood at the venous end outlet of the dialyzer 4 flows back to the venous pot 13. At the same time, the replacement fluid enters the venous pot 13 through the replacement pump 12, and hemodialysis is carried out in the way of diffusion and convection, which is the fourth plasma and blood purification. Ensure the balance of input and output: filtrate volume ml / h + waste liquid volume ml / h = dialysate + replacement fluid volume ml / h. If hypovolemic dehydration or ultrafiltration is required, then filtrate volume ml / h + waste liquid volume ml / h < dialysate + replacement fluid volume ml / h according to the need. The QPPS system has the functions of continuously filtering and removing medium and small molecular toxins, endotoxins, inflammatory mediators, cytokines, regulating the balance of water, electrolyte and acid-base, improving renal function, and at the same time can also remove macromolecular pathogenic substances such as triglycerides, cholesterol, fatty acids, immune complexes, etc. The treatment time is 6 - 10 h. To prevent treatment allergy, dexamethasone H20130301, 5 mg, Pfizer Belgium 5 mg + 5% calcium gluconate 20 ml are intravenously injected before treatment; the anticoagulant is selected as low molecular weight heparin sodium injection H31022051, 4000 U, Shanghai No. 1 Biochemical Pharmaceutical Co., Ltd., and the dosage is determined according to the patient's coagulation function. The whole process monitors indicators such as electrocardiogram, blood pressure, oxygen saturation, etc., and closely observes the changes in the patient's condition.

[0037] In this embodiment, the quadruple plasma blood purification device provided by the present application is a new blood purification mode for treating hyperlipidemia-induced acute severe pancreatitis, which can simultaneously remove large, medium and small molecule toxins, continuously improve renal function and balance the internal environment, does not require plasma, and has the effect of preventing and treating multiple organ failure; the device can complete the removal of large molecules such as triglycerides, immunoglobulins, and small and medium molecules such as cytokines, endotoxins, and inflammatory factors in the blood within 6-10 hours, improve renal function, regulate water-electrolyte acid-base balance, etc., and is a short-term treatment for lipid-induced acute severe pancreatitis. It can block the four major pathogenesis of high triglycerides, cytokine storm sepsis, internal environment disorder and renal insufficiency at one time; it combines the core technology of double plasma exchange with continuous hemofiltration dialysis and plasma perfusion technology, and combines the technical essentials of non-bioartificial liver and hemodialysis technology, while completing the blood purification work of nephrology and gastroenterology. This innovative technology can solve the four major pathogenesis in a short time, buy more effective treatment time for the lives of critically ill patients, reduce the risk of further deterioration of the disease, improve the clinical treatment rate, reduce the mortality rate, and save social medical costs.

[0038] The present application integrates the two technologies of non-bioartificial liver and hemodialysis into one, and only requires a one-time surgical treatment of 6-10 hours, without the need for multiple or alternate-day surgeries. At the same time, it solves the problems of hypertriglyceridemia, cytokine storm sepsis, pathogenesis of internal environment disorders, and renal insufficiency that lead to pancreatitis, reduces the risk of death, and improves the clinical rescue rate; and only requires a set of blood purification pathways, a primary plasma separator 1, a secondary plasma separator 2, a blood filter, and a perfusion device 3, and does not rely on plasma, has low cost, is easy to operate, and consumes less time, manpower, and financial resources.

[0039] The present application provides a purification method of a quadruple plasma blood purification device, comprising:

[0040] The primary plasma separator 1 uses the OP-08 membrane to separate the patient's blood and separate the whole plasma;

[0041] Secondary plasma separator 2 uses EC-50 membrane to remove large molecules from whole plasma;

[0042] The perfusion device 3 performs adsorption removal on the whole plasma from which the macromolecules are removed, so as to remove the middle molecular toxins therein, and transmits the treated blood to the dialyzer 4;

[0043] The dialyzer 4 is used to dialyze the dialysate, the blood cells output from the primary plasma separator 1 and the treated blood by diffusion and convection, and to input the dialyzed blood into the patient's vein.

[0044] In a specific embodiment, before the step of using the OP-08 membrane by the primary plasma separator 1 to separate the patient's blood and separating out the whole plasma, it further includes:

[0045] Intravenously inject 5 mg of dexamethasone + 5%, 20 ml of calcium gluconate, and an anticoagulant into the patient; wherein, the anticoagulant is low molecular weight heparin sodium injection.

[0046] In a specific embodiment, in the step where the dialyzer 4 is used to perform dialysis treatment on the dialysate, the blood cells output by the primary plasma separator 1, and the processed blood in a diffusion and convection manner,

[0047] When in balance of inflow and outflow: filtrate volume ml / h + waste liquid volume ml / h = dialysate + replacement fluid volume ml / h;

[0048] When dehydrating or ultrafiltrating: filtrate volume ml / h + waste liquid volume ml / h < dialysate + replacement fluid volume ml / h.

[0049] In this embodiment, the present application provides a method for using a quadruple plasma blood purification device, as follows:

[0050] (I) Startup preparation

[0051] 1. Turn on the switch behind the JUN-55X machine, press the

Preparation

Operation

Execute

[0052] 2. Touch the

Set Operating Conditions

Custom Mode

[0053] 3. Touch the

Set Alarm Conditions

Set Alarm Pressure

[0054]

[0055] 4. Installation sequence of the CHDP pipeline

[0056] The first step: Install the arterial pipeline (red mark), and install it according to the installation instruction diagram of the arterial pipeline on the machine: arterial chamber 14 - arterial pump 5 tube - close the cover of arterial pump 5 - blood flow insufficient monitoring liquid pillow

[0057] The second step: Install the venous pipeline (blue mark), and install it according to the installation instruction diagram of the venous pipeline on the machine: venous chamber 13 - air detection;

[0058] The third step: Install the extracorporeal pipeline of the first-stage membrane plasma separator (brown and green marks):

[0059] Filter fluid pot - blood leakage monitoring - dialysate pump tube - close the dialysate pump cover. Note that the green marked pipeline is on the left;

[0060] Step 4: Install the yellow mark on the filtrate pipeline:

[0061] Filtered liquid metering chamber - Filtered liquid flow control valve - Filtered liquid pump tube - Close the Filtered liquid pump cover

[0062] Step 5: Install the replacement fluid line blue:

[0063] Replacement fluid infusion pipeline - flow control valve - replacement fluid metering chamber - replacement fluid pump tube - close the replacement fluid pump cover - connect the blue marked end of the replacement fluid pump tube to the blue marked end of the front end pipeline of the intravenous pot 13.

[0064] Step 6: Install the outer membrane pipeline of the plasma component separator:

[0065] After the white-marked end of the plasma component separator membrane outer tube is connected to the arterial end of the perfusion device 3, the plasma and blood are collected through the three-way extension tube between the venous end of the perfusion device 3 and the venous end of the primary membrane, and the collected blood is connected to the white-marked end of the hemofilter arterial end;

[0066] Step 7: Install the blood filter membrane outer pipeline and loop red and blue:

[0067] The venous end of the blood filter is connected to the venous pot 13 through the red and blue tubes, the upper end outside the membrane is connected to the blue tube behind the replacement pump 12, and the lower end outside the membrane is connected to the yellow tube of the waste pump 7;

[0068] Step 8: Connect all monitoring pressure lines to the pressure sensor protection cover, and use the three-way valve OFF arrow on the line to point to the end that indicates this end is closed, and keep the pressure monitoring in the monitoring state. Arterial pressure, venous pressure, filtration pressure, external pressure;

[0069] Step 9: Connect the metering pot to the pressure sensor protective cover. Replacement fluid, filtrate

[0070] 2. QPPS pre-rinse

[0071] Flushing volume: 4000 ml of liquid, including 2000 ml of normal saline and 2000 ml of 5% heparinized saline.

[0072] Rinse steps:

[0073] 1. Insert the replacement fluid needle into the saline solution and place the replacement fluid empty monitor and dialysate empty detector.

[0074] 2. Connect the infusion tube on the arterial line to 1000 ml of normal saline. First, pre-flush the blood-drawing end of the arterial line using gravity. After it is filled, clamp the blood-drawing end of the artery with a hemostat.

[0075] 3. Set the blood pump speed to 50 ml / min and the speeds of other pumps to 0.

[0076] 4. Press [Linkage Start] to flush the arterial line. When the liquid enters the arterial chamber 14, remove the arterial chamber 14 from the machine, invert the arterial chamber 14 for pre-flushing. When the pre-flushing liquid reaches 3 / 4 of the chamber, adjust the arterial chamber 14 and re-place it on the machine. When the liquid flows out from the inlet end of the arterial filter, use a hemostat to clamp the liquid outflow end, and press [Linkage Stop].

[0077] 5. Connect all ports of the separator. After confirming that the separator is connected to all the pipelines, loosen all the hemostats on the pipelines.

[0078] 6. Set the blood pump speed to 100 ml / min and the dialysis fluid speed to 3000 ml / h, and the speeds of other pumps to 0. Press [Linkage Start] to start pre-flushing. When the liquid enters the filtrate chamber, remove the filtrate chamber from the machine, invert the filtrate chamber for pre-flushing. When the pre-flushing liquid reaches 3 / 4 of the chamber, adjust the filtrate chamber and re-place it on the machine to continue pre-filling. When the liquid flows out from the pipeline, use a hemostat to clamp the liquid outflow end. Press [Linkage Stop].

[0079] 7. Connect each port of the plasma component separator to the pipeline. After connection, loosen all the pliers on the pipeline.

[0080] 8. Set the replacement fluid pump to 3000 ml / h and the filtrate pump speed to 2000 ml / h. Press [Linkage Start] to start pre-flushing.

[0081] 9. When the liquid enters the venous chamber 13, remove the venous chamber 13 from the machine, invert the venous chamber 13 for pre-flushing. When the pre-flushing liquid reaches 3 / 4 of the chamber, adjust the venous chamber 13 and re-place it on the machine to continue pre-filling.

[0082] 10. Pay attention to observing the pre-flushing liquid on the arterial side and the replacement fluid side to prevent the liquid from running out and air from entering.

[0083] 11. When replacing the pre-flushing liquid, touch [Linkage Stop]. To restart pre-flushing, touch [Linkage Start] until pre-flushing is completed, and then press [Linkage Stop] again.

[0084] 12. After pre-flushing is completed, press Monitor [OFF].

[0085] 13. Set the speeds of all pumps to 0.

[0086] 14. Clamp the connection ends of the arteriovenous tubing and wait for connection for treatment.

[0087] III. Treatment

[0088] Use separate arteriovenous connections:

[0089] 1. Clamp the arterial blood sampling tubing with a hemostat and connect the arterial blood sampling tubing to the arterial end of the double-lumen catheter. Pay attention not to let air bubbles enter during connection.

[0090] 2. Turn on the blood pump at 10 ml / min and gradually increase the speed to 30 - 50 mL / min. When blood enters the venous chamber 13, turn off the blood pump, clamp the venous tubing with a hemostat, and connect the venous tubing to the venous end of the double-lumen catheter. Pay attention not to let air bubbles enter during connection.

[0091] 3. After confirming the tight connection, release all the hemostats, turn on the blood pump, and set the flow rate to 30 - 50 mL / min.

[0092] 4. Press the monitoring [ON] key to start the treatment.

[0093] 5. Set the speed of the dialysate pump, replacement fluid pump, and filtrate pump 10 according to the blood pump flow rate of the therapist. The proportional relationship is:

[0094] Dialysate pump / blood pump speed is 20 - 30% × 60

[0095] The speed of the waste liquid pump 7 is 50 - 100 ml / h,

[0096] Replacement fluid pump speed = Filtrate pump speed + Waste liquid pump 7 speed.

[0097] The dosage of anticoagulant and the target treatment volume are calculated individually according to the specific situation of the patient.

[0098] 6. After the blood pump runs for 10 minutes, the blood pump speed is preferably up to 30 ml / min, and press [Linkage Start].

[0099] 7. After the treatment starts, as the external pressure and the pressure inside the secondary membrane increase, the speed of the filtrate pump can be adjusted at any time, but the maximum ratio does not exceed 20% of the dialysate pump speed. The replacement fluid pump is for supplementary fluid, and the filtrate pump is for discarded fluid. The treatment requires that the supplementary fluid and the discarded fluid are equal in amount.

[0100] 8. During the treatment process, the speed of the blood pump is maintained at 50 - 150 ml / min.

[0101] 9. The treatment time is 6 - 10 hours.

[0102] 10. During the treatment process, if the tubing is blocked due to too high triglyceride levels, the TMP rises rapidly, etc., it is necessary to flush the tubing with normal saline again.

[0103] Four blood returns

[0104] 1. Touch monitoring

OFF

[0105] Blood return: Adjust the blood pump speed to about 50 - 100 mL / min, turn on the blood pump, and transfuse the blood in the plasma separator membrane back with normal saline until the liquid in the venous chamber 13 turns pink, then turn off the blood pump. ② Plasma return: Clamp the A, B, C, and D ports separately with pliers, separate these four ports, connect port B to port C, then open the pliers of port B and port C again, and inject air with the replacement fluid pump to transfuse the plasma outside the secondary plasma separator 2EC series membrane. Set the replacement fluid pump speed to 3000 mL / h. Turn on the replacement fluid pump, and plasma return begins. Until the plasma is completely transfused, the treatment ends.

[0106] For those skilled in the art, it is obvious that the present invention is not limited to the details of the above exemplary embodiments, and without departing from the spirit or basic characteristics of the present invention, the present invention can be implemented in other specific forms. Therefore, from any point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the appended claims rather than the above description. Therefore, all changes falling within the meaning and scope of the equivalent elements of the claims are intended to be included in the present invention. Any reference signs in the claims should not be regarded as limiting the claims involved.

[0107] In addition, it should be understood that although this specification is described according to embodiments, not every embodiment only contains an independent technical solution. This narrative way of the specification is only for clarity. Those skilled in the art should regard the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.

Claims

1. A quadruple plasma blood purification device, characterized in that: include: A primary plasma separator (1), a secondary plasma separator (2), a perfusion device (3), and a dialyzer (4); The inlet of the primary plasma separator (1) is connected to the patient's artery and is used to receive the patient's plasma and separate whole plasma; The inlet of the secondary plasma separator (2) is connected to the primary plasma separator (1) and is used to remove macromolecules in whole plasma through the membrane; The inlet of the perfusion device (3) is connected to the secondary plasma separator (2) and is used to adsorb and remove middle molecular toxins from the plasma after the macromolecules are removed; The dialyzer (4) is connected to the perfusion device (3) and the primary plasma separator (1) respectively, and is used to receive the plasma from which the middle molecule toxins are removed and the blood cells from the primary plasma separator (1). Dialysis fluid is pumped into the upper end of the dialyzer (4) and mixed with the plasma from which the middle molecule toxins are removed and the blood cells for dialysing. The filtrate is discarded at the lower end of the dialyzer (4), and the venous outlet of the dialyzer (4) transports the blood back to the patient's vein.

2. The quadruple plasma blood purification device according to claim 1, characterized in that: An arterial pump (5) and an arterial pump (5) are sequentially arranged on a pipeline connecting the inlet of the primary plasma separator (1) and the patient's artery; the arterial pump (5) is used to deliver the patient's blood from the artery into the primary plasma separator (1).

3. The quadruple plasma blood purification device according to claim 1, characterized in that: A separation pump (6) is provided on the connecting pipeline between the primary plasma separator (1) and the secondary plasma separator (2), and is used to pump the plasma from which macromolecules have been removed to the bottom inlet of the secondary plasma separator (2); the top outlet of the secondary plasma separator (2) is connected to a waste liquid bag (8) via a waste liquid pump (7).

4. The quadruple plasma blood purification device according to claim 1, characterized in that: The perfusion device (3) delivers plasma from which middle molecular toxins have been removed to the bottom inlet of the dialyzer (4), and the primary plasma separator (1) delivers blood cells to the bottom inlet of the dialyzer (4); the dialyzer (4) is connected to a filtrate bag (11) via a filtrate pump (10); The top venous outlet of the dialyzer (4) transports the blood back to the patient's vein through a venous pot (13).

5. The quadruple plasma blood purification device according to claim 4, characterized in that: It also includes a replacement pump (12), which is used to input replacement fluid into the venous pot (13) and mix it with the blood output by the dialyzer (4) and input it into the patient's vein.

6. The quadruple plasma blood purification device according to claim 1, characterized in that: The dialysate is pumped into the dialyzer (4) via a dialysate pump (9).

7. The quadruple plasma blood purification device according to claim 1, characterized in that: The primary plasma separator (1) is provided with an OP-08 membrane; the pore size of the OP-08 membrane is 0.3 μm; the secondary plasma separator (2) is provided with an EC-50 membrane; the pore size of the EC-50 membrane is 0.035 μm.

8. A purification method for a quadruple plasma blood purification device, characterized in that: include: The primary plasma separator (1) uses the OP-08 membrane to separate the patient's blood and separate the whole plasma; The secondary plasma separator (2) uses EC-50 membrane to remove large molecules from whole plasma; The perfusion device (3) performs adsorption removal on the whole plasma from which the macromolecules have been removed, so as to remove the middle molecular toxins therein, and transports the treated blood to the dialyzer (4); The dialyzer (4) is used to dialyze the dialysate, the blood cells output from the primary plasma separator (1), and the treated blood by diffusion and convection, and to input the dialyzed blood into the veins of the patient.

9. The purification method of the quadruple plasma blood purification device according to claim 8, characterized in that: The primary plasma separator (1) uses the OP-08 membrane to separate the patient's blood and separate the whole plasma, and also includes: The patient was given intravenous injection of dexamethasone 5mg+5%, calcium gluconate 20ml, and anticoagulant; the anticoagulant was low molecular weight heparin sodium injection.

10. The purification method of the quadruple plasma blood purification device according to claim 8, characterized in that: The dialyzer (4) is used to dialyze the dialysate, the blood cells output from the primary plasma separator (1) and the treated blood by diffusion and convection. When the inflow and outflow are balanced: filtrate volume (ml / h) + waste volume (ml / h) = dialysate + replacement fluid volume (ml / h); During dehydration or ultrafiltration: filtrate volume (ml / h) + waste fluid volume (ml / h) < dialysate + replacement fluid volume (ml / h).

Images